This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Park, H.-S. Articles by Kwak, J.-H. Search for Related Content PubMed PubMed Citation Articles by Park, H.-S. Articles by Kwak, J.-H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2006, p. 2261-2264, Vol. 50, No. 6
0066-4804/06/$08.00+0     doi:10.1128/AAC.01407-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

In Vitro and In Vivo Antibacterial Activities of DW-224a, a New Fluoronaphthyridone

School of Life and Food Sciences, Handong Global University, Kyungbuk, Republic of Korea,¹ Dong Wha Pharmaceutical Industry Ltd., Anyang City, Republic of Korea,² College of Pharmacy, Seoul National University, Seoul, Republic of Korea³

Received 31 October 2005/ Returned for modification 27 December 2005/ Accepted 21 March 2006

DW-224a showed the most potent in vitro activity among the quinolone compounds tested against clinical isolates of gram-positive bacteria. Against gram-negative bacteria, DW-224a was slightly less active than the other fluoroquinolones. The in vivo activities of DW-224a against gram-positive bacteria were more potent than those of other quinolones.

This article has been cited by other articles:

• Park, H. S., Yoon, Y. M., Jung, S. J., Kim, C. M., Kim, J. M., Kwak, J.-H. (2007). Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. J Antimicrob Chemother 60: 568-574 [Abstract] [Full Text]